Advertisement
UK markets closed

  • FTSE 100

    8,075.62
    +35.24 (+0.44%)
     

  • FTSE 250

    19,594.82
    -124.55 (-0.63%)
     

  • AIM

    753.05
    -1.64 (-0.22%)
     

  • GBP/EUR

    1.1650
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2495
    +0.0033 (+0.26%)
     

  • Bitcoin GBP

    51,113.64
    -790.59 (-1.52%)
     

  • CMC Crypto 200

    1,375.39
    -7.19 (-0.52%)
     

  • S&P 500

    5,011.14
    -60.49 (-1.19%)
     

  • DOW

    37,869.70
    -591.22 (-1.54%)
     

  • CRUDE OIL

    82.22
    -0.59 (-0.71%)
     

  • GOLD FUTURES

    2,345.20
    +6.80 (+0.29%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,920.22
    -168.48 (-0.93%)
     

  • CAC 40

    8,017.59
    -74.27 (-0.92%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

U.S. FDA lifts hold on AstraZeneca head and neck cancer trials

Reuters - UK Focus

LONDON, Nov 22 (Reuters) - U.S. officials have given a green light for two clinical trials testing AstraZeneca (NYSE: AZN - news) 's cancer immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding.

The British drugmaker said on Tuesday that one of the late-stage Phase III trials had already re-opened for new patient enrolment and the second was expected to resume recruitment shortly.

News of the partial hold on the trials, imposed at the end of last month, had spooked investors since durvalumab is AstraZeneca's most important pipeline medicine. (Reporting by Ben Hirschler; Editing by Mark Potter)